Literature DB >> 28603463

Case Report: Two Cases of Nicolau Syndrome Associated with Glatiramer Acetate.

Dorlan J Kimbrough, Scott D Newsome.   

Abstract

We report two cases of Nicolau syndrome (embolia cutis medicamentosa), a rare complication of injectable medications, both associated with the administration of 20 mg of subcutaneous glatiramer acetate. Both patients required surgical debridement and were subsequently treated conservatively without additional complications. Patient 1 opted to discontinue disease-modifying therapy. Patient 2 continued glatiramer acetate therapy without complications by using other injection sites. These cases highlight the need for prompt investigation of new unusual skin lesions in patients receiving injectable multiple sclerosis treatments (regardless of length of treatment and previous minor cosmetic concerns) and illustrate the clinical distinction between Nicolau syndrome and drug-induced skin necrosis.

Entities:  

Year:  2017        PMID: 28603463      PMCID: PMC5460868          DOI: 10.7224/1537-2073.2016-038

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  10 in total

1.  [Nicolau syndrome after administration of glatiramer acetate].

Authors:  A Pulido Pérez; V Parra Blanco; R Suárez Fernández
Journal:  Neurologia       Date:  2012-06-13       Impact factor: 3.109

2.  Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.

Authors:  Viola Harde; Thomas Schwarz
Journal:  J Dtsch Dermatol Ges       Date:  2007-12       Impact factor: 5.584

3.  Nicolau syndrome following subcutaneous glatiramer-acetate injection.

Authors:  Silvia Koller; Birger Kränke
Journal:  J Am Acad Dermatol       Date:  2011-02       Impact factor: 11.527

4.  [Embolia cutis medicamentosa (Nicolau syndrome) after glatiramer acetate injection].

Authors:  C Martínez-Morán; P Espinosa-Lara; L Nájera; A Romero-Maté; S Córdoba; A Hernández-Núñez; J Borbujo
Journal:  Actas Dermosifiliogr       Date:  2011-07-08

5.  [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].

Authors:  C Gaudez; S Regnier; S Aractingi; O Heinzlef
Journal:  Rev Neurol (Paris)       Date:  2003-05       Impact factor: 2.607

6.  Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Peter Rieckmann; Alexey Boyko; Krzysztof Selmaj; Robert Zivadinov
Journal:  Ann Neurol       Date:  2013-06-28       Impact factor: 10.422

7.  Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management.

Authors:  E M Frohman; K Brannon; Sherry Alexander; D Sims; J T Phillips; S O'Leary; K Hawker; M K Racke
Journal:  Mult Scler       Date:  2004-06       Impact factor: 6.312

8.  Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone).

Authors:  N Kluger; E Thouvenot; W Camu; B Guillot
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-04-08       Impact factor: 6.166

9.  Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.

Authors:  Catherine M Edgar; Donald G Brunet; Paul Fenton; E Vee McBride; Peter Green
Journal:  Can J Neurol Sci       Date:  2004-02       Impact factor: 2.104

10.  Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.

Authors:  Chiara Zecca; Carlo Mainetti; Roland Blum; Claudio Gobbi
Journal:  BMC Neurol       Date:  2015-12-02       Impact factor: 2.474

  10 in total
  2 in total

1.  Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate.

Authors:  Lyubomira Vlahova; Lutz Kretschmer; Michael P Schön; Rotraut Mössner
Journal:  Case Rep Dermatol       Date:  2021-02-16

Review 2.  Nicolau syndrome following subcutaneous glatiramer acetate injection: A case report and review of the literature.

Authors:  Pelin Esme; Irfan Gahramanov; Egemen Akıncıoglu; Gulsen Akoglu
Journal:  Indian J Pharmacol       Date:  2021 Nov-Dec       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.